Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC), a Delaware corporation, with a report date of January 4, 2023. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's continued listing status.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the stock price compliance issue.
Material Changes
The material event reported is the receipt of a Nasdaq deficiency notice. The company's common stock failed to meet the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days prior to January 4, 2023, as required by Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an automatic 180-calendar-day grace period to regain compliance, ending on July 3, 2023.
- Compliance Criteria: To regain compliance, the common stock must close at or above $1.00 per share for a minimum of 10 consecutive business days before the deadline.
- Trading Status: The notice has no immediate effect on the listing or trading of the stock; it will continue to trade under the symbol "CYCC."
- Delisting Risk: If compliance is not achieved within the allotted period (including any potential extensions), the stock will be subject to delisting from the Nasdaq Capital Market.
- Management Action: The company intends to monitor bid prices and may consider a reverse stock split to achieve compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of CYCC common stock relative to the $1.00 threshold.
- Monitor official company announcements for any declaration of a reverse stock split.
- Track the number of consecutive business days the stock trades above $1.00 to determine if the 10-day compliance window is met.
- Review future filings for updates on the grace period status or potential appeals if delisting is threatened.